Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion
OTCMKTS:TLOG

TetraLogic Pharmaceuticals (TLOG) Stock Price, News & Analysis

TetraLogic Pharmaceuticals logo

About TetraLogic Pharmaceuticals Stock (OTCMKTS:TLOG)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TetraLogic Pharmaceuticals Corporation was a clinical-stage biopharmaceutical company focused on developing small-molecule medicines designed to activate programmed cell death, or apoptosis. Its research was primarily aimed at creating treatments for cancer and other serious diseases.

The company’s best-known investigational product was birinapant, also known as TL32711, a SMAC mimetic intended to promote the death of cancer cells and improve the effectiveness of other therapies. Birinapant was evaluated in clinical studies for several cancer indications, including certain blood cancers and solid tumors.

TetraLogic was based in Malvern, Pennsylvania, and operated primarily as a development-stage company rather than a commercial pharmaceutical manufacturer. Publicly available information about its current operations, leadership, product portfolio and geographic activities is limited, and its historical drug-development programs do not indicate an established marketed product business.

AI Generated. May Contain Errors.

Receive TLOG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TetraLogic Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLOG Stock News Headlines

TetraLogic Pharmaceuticals Corp.
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
TetraLogic Pharmaceuticals Corp (TLOG)
TetraLogic Pharmaceuticals Corporation (TLOG)
Inovio Pharmaceuticals, Inc. Common Stock (INO)
TetraLogic Pharma (TLOG) Earnings Dates & Reports
See More Headlines

TLOG Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that TetraLogic Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Zafgen (ZFGN), Actinium Pharmaceuticals (ATNM), Achieve Life Sciences (ACHV) and Arrowhead Pharmaceuticals (ARWR).

Company Calendar

Today
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:TLOG
Previous Symbol
NASDAQ:TLOG
CIK
1361248
Employees
29
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
4.52
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (OTCMKTS:TLOG) was last updated on 10/28/2026 by MarketBeat.com Staff.
From Our Partners